Clinical Trial Update: CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating CLL-1/CD33-targeted LCAR-AMDR CAR-T cells for relapsed or refractory acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• LCAR-AMDR CAR-T cells targeting CLL-1/CD33 (CLL-1/CD33-targeted CAR-T cells)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED